Cure8 research brief
Patients with IBD who may need dupilumab for another immune condition could benefit from evidence about whether combining dupilumab with IBD biologics or advanced therapies changes infection or healthcare-utilization risks. This study provides preliminary real-world data but is small.
Patients on biologics or other advanced IBD therapies, clinicians managing patients with overlapping immune-mediated diseases (IBD and eosinophilic esophagitis/atopic disease), and researchers studying combination immune-modifying therapy safety.
This retrospective cohort from the All of Us dataset identified 12 patients with documented overlap of dupilumab and other advanced IBD therapies and compared them with a much larger group on advanced therapy alone.
The authors report no statistically significant increase in selected infectious outcomes (pneumonia, sepsis, cellulitis, herpes zoster), hospitalizations, or ED visits among the small concurrent-exposure group, but the number of dual-exposed participants was very small.
Because the concurrent-exposure group was uncommon and underpowered, these results are preliminary and cannot rule out uncommon or rare risks. The study supports the need for larger, disease-specific investigations (for example, focused on patients with both IBD and eosinophilic esophagitis) before routine clinical conclusions can be drawn.
Small number (12) of concurrent-exposed participants limits statistical power; outcomes were identified via diagnosis codes in a retrospective dataset, and the study was not disease-specific to IBD+EoE patients.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Competing interests: The authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This real-world, multicenter study suggests risankizumab can induce clinical and steroid-free remission and mucosal healing in many patients with Crohn disease who previously failed advanced therapies, which may be...
Patients with moderate-to-severe Crohn's disease who do not respond to anti-TNF drugs have limited options. This study suggests combining ustekinumab with upadacitinib may improve endoscopic healing versus either drug...
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...
